IMbrave150: A randomised phase III study of atezolizumab 1 bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

被引：0
|
作者：
Qin, S. [1 ]
Cheng, A-L. [2 ]
Ducreux, M. P. [3 ]
Galle, P. R. [4 ]
Zhu, A. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Ikeda, M. [10 ]
机构：
[1] Peoples Liberat Army 81 Hosp, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Gustave Roussy, Gastrointestinal Unit, Villejuif, France
[4] Univ Med Mainz, Dept Internal Med, Mainz, Germany
[5] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Seoul Natl Univ, Med Oncol Ctr, Coll Med, Seoul, South Korea
[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA
[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
210TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
    Li, Daneng
    Toh, Han Chong
    Merle, Philippe
    Tsuchiya, Kaoru
    Hernandez, Sairy
    Verret, Wendy
    Nicholas, Alan
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (06) : 558 - 571
  • [22] IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Cheng, A-L.
    Qin, S.
    Ikeda, M.
    Galle, P.
    Ducreux, M.
    Zhu, A.
    Kim, T-Y.
    Kudo, M.
    Breder, V.
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Xu, Z.
    Hernandez, S.
    Liu, J.
    Huang, C.
    Mulla, S.
    Lim, H. Y.
    Finn, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
    Espinoza, Magdalena
    Muquith, Maishara
    Lim, Mir
    Zhu, Hao
    Singal, Amit G.
    Hsiehchen, David
    GASTROENTEROLOGY, 2023, 165 (01) : 286 - +
  • [24] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [25] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients (pts) with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Qian, Yuquan
    Liu, Baojiang
    Weiss, Christel
    Zhu, Xu
    Teufel, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 79 - 79
  • [26] Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
    Chon, H.
    Song, Y. S.
    Yang, H.
    Kim, I.
    Hye-Young, K.
    Lee, W. S.
    Sang, Y. B.
    Kim, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S611 - S611
  • [27] IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
    Badhrinarayanan, Shreya
    Cotter, Christopher
    Zhu, Huaqi
    Lin, Ya-Chen
    Kudo, Masatoshi
    Li, Daneng
    FUTURE ONCOLOGY, 2024, 20 (28) : 2049 - 2057
  • [28] Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
    Yim, Sun Young
    Lee, Sung Hwan
    Baek, Seung-Woo
    Sohn, Bohwa
    Jeong, Yun Seong
    Kang, Sang-Hee
    Park, Kena
    Park, Hyewon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Park, Young Nyun
    Leem, Sun-Hee
    Curran, Michael A.
    Kim, Ji Hoon
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [29] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [30] Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
    Fulgenzi, Claudia A. M.
    Murphy, Cian
    D'Alessio, Antonio
    Scheiner, Bernhard
    Pinter, Matthias
    Cortellini, Alessio
    Pinato, David J. James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 597 - 597
12345